These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21048244)

  • 1. Plasma efavirenz in HIV infected children treated with generic antiretroviral drugs in India.
    Ramachandran G; Kumar AK; Vasantha M; Shah I; Swaminathan S
    Indian Pediatr; 2010 Oct; 47(10):890-1. PubMed ID: 21048244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
    Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
    Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Branded Versus Generic Efavirenz Formulation in HIV-Infected Patients.
    Gervasoni C; Baldelli S; Cerea M; Cenderello G; Bini T; Vimercati S; Iardino R; Gazzaniga A; DʼArminio Monforte A; Clementi E; Cattaneo D
    Ther Drug Monit; 2016 Jun; 38(3):420-2. PubMed ID: 26727626
    [No Abstract]   [Full Text] [Related]  

  • 5. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
    Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
    Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
    Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
    Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does tenofovir influence efavirenz pharmacokinetics?
    Rotger M; Colombo S; Furrer H; Décosterd L; Buclin T; Telenti A
    Antivir Ther; 2007; 12(1):115-8. PubMed ID: 17503755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children.
    Viljoen M; Gous H; Kruger HS; Riddick A; Meyers TM; Rheeders M
    AIDS Res Hum Retroviruses; 2010 Jun; 26(6):613-9. PubMed ID: 20507205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evidence-based therapeutic drug monitoring for efavirenz].
    Solas C; Gagnieu MC;
    Therapie; 2011; 66(3):197-205. PubMed ID: 21819803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.
    von Hentig N; Koenigs C; Elanjikal S; Linde R; Dunsch D; Kreuz W; Funk MB
    Eur J Med Res; 2006 Sep; 11(9):377-80. PubMed ID: 17101460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
    Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
    Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anticoagulants on plasma nevirapine and efavirenz concentrations.
    Hemanth Kumar AK; Ramachandran G; Kumar P; Anitha S; Rajasekaran S; Swaminathan S
    Ther Drug Monit; 2007 Oct; 29(5):652-4. PubMed ID: 17898659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
    Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
    Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy and bone mineral measurements in HIV-infected youths.
    Zuccotti G; Viganò A; Gabiano C; Giacomet V; Mignone F; Stucchi S; Manfredini V; Marinacci F; Mora S
    Bone; 2010 Jun; 46(6):1633-8. PubMed ID: 20211284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients.
    Grilo NM; Correia MJ; Sequeira C; Harjivan SG; Caixas U; Diogo LN; Marques MM; Monteiro EC; Antunes AM; Pereira SA
    Toxicol Lett; 2016 Oct; 260():28-35. PubMed ID: 27543169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.